Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 2 |
| Emerging Market for Clinical Trials - China Introduction | 9 | 2 |
| GBI Research Report Guidance | 10 | 1 |
| Emerging Market for Clinical Trials - China Overview | 11 | 17 |
| The Clinical Research Process Overview | 11 | 1 |
| Drug Discovery | 11 | 1 |
| Pre-Clinical | 12 | 1 |
| Phase I | 12 | 1 |
| Phase II | 12 | 1 |
| Phase III | 12 | 1 |
| Review and Approval from the Regulatory Agencies | 12 | 1 |
| Post-marketing Studies | 12 | 1 |
| Clinical Trial Design and Types | 13 | 1 |
| Types of Design | 13 | 1 |
| Parallel Group Trial Design | 13 | 1 |
| Cross over Trial Design | 14 | 1 |
| Adaptive Clinical Trial Design | 15 | 2 |
| Wyeth s Learn and Confirm Model | 17 | 2 |
| Role of CROs | 19 | 1 |
| Sponsors of Clinical Trials | 20 | 1 |
| Intellectual Property Protection in China | 21 | 1 |
| Article 15 | 21 | 1 |
| Aritcle 20 | 22 | 1 |
| Articles 22 and 23 | 22 | 1 |
| Article 62 | 22 | 1 |
| Articles 48 and 50 | 22 | 1 |
| Article 69(5) | 22 | 1 |
| Article 5 and 26 | 22 | 1 |
| The Need for Outsourcing Clinical Trials | 23 | 1 |
| High Risks and Costs Associated With Drug Development | 23 | 1 |
| Escalating Costs of Clinical Trials | 24 | 1 |
| Global Increase in the Number of Clinical Trials Conducted | 25 | 1 |
| Restructuring the R&D | 25 | 1 |
| Increased Screening Rates during R&D | 26 | 1 |
| Expiring Patents Pressurize Pharmaceutical Companies to Reduce Costs | 27 | 1 |
| Emerging Market for Clinical Trials China - Clinical Trial Trends | 28 | 16 |
| Registration of Phase l Clinical Trials | 28 | 1 |
| Registration of Phase ll Clinical Trials | 29 | 1 |
| Registration of Phase lll Clinical Trials | 30 | 1 |
| Registration of Phase lV Clinical Trials | 31 | 1 |
| Clinical Trials Registered in 2010 | 32 | 1 |
| Comparative Analysis of Registered Clinical Trials in Brazil, Russia, India and China (BRIC) Countries | 33 | 1 |
| Comparative Analysis of Population Statistics in BRIC Countries | 34 | 1 |
| Population Forecast of China | 35 | 1 |
| Analysis of Epidemiology and Prevalence of Major Diseases in China | 36 | 1 |
| Number of Recruiting Sites for Major Therapeutics in China | 36 | 1 |
| Number of Recruiting Sites by Multinational Companies (MNCs) in China | 37 | 1 |
| Number of Clinical Trials Carried Out By Multinational Companies in China | 38 | 1 |
| Number of Clinical Trials Carried out by MNC s in Hong Kong | 39 | 1 |
| Number of Major State Food and Drug Administration (SFDA) Accredited Study Sites in China | 40 | 2 |
| Number of SFDA Accredited Institutions for Therapeutic Areas | 42 | 2 |
| Emerging Market for Clinical Trials China - Market Environment Characterization | 44 | 22 |
| Increase in Growth of Global CRO Market will Foster the Growth of Chinese Clinical Trial Market | 44 | 1 |
| Increase in Multinational Sites to Conduct Clinical Trials will Drive the Clinical Trial Market in China | 45 | 2 |
| Access to a Large Patient Population | 47 | 1 |
| Comparison of Population of Different Countries | 48 | 1 |
| Patient Availability for Major Diseases | 49 | 1 |
| Number of Major Infections in China | 49 | 1 |
| Number of Deaths Occurring by Diseases in China | 50 | 1 |
| HIV/AIDS | 51 | 1 |
| Cardiovascular Diseases (CVD) | 52 | 1 |
| Diabetes | 53 | 1 |
| Cancer | 54 | 1 |
| Chronic Obstructive Pulmonary Diseases (COPD) | 55 | 1 |
| Subject Recruitment and Speed of Trials | 56 | 1 |
| Cost Comparison China Vs the US | 56 | 1 |
| Annual Median Salaries of Doctors in China | 57 | 1 |
| Annual Median Salaries of Doctors in Different Provinces of China | 58 | 1 |
| Infrastructural Facilities Improve the Clinical Trial Environment | 59 | 1 |
| Health Care Institutions in China in 2009 | 59 | 1 |
| Growth of Health Care Professionals in China | 60 | 1 |
| Increase in Number of Graduates in Colleges and Universities of China | 61 | 1 |
| Number of Graduates Registered in Colleges and Universities | 61 | 1 |
| Number of Graduates in Medical Colleges | 62 | 1 |
| Increase in Principal Investigators | 63 | 1 |
| Market Restraints | 64 | 1 |
| Slow Regulatory Approvals | 64 | 1 |
| Insufficient Communication Platform | 64 | 1 |
| Intellectual Property Issues are not Fully Resolved | 64 | 1 |
| In depth Training in Good Clinical Practices (GCP) for Health Care Professionals | 64 | 1 |
| Clinical Trial Market Size in China | 65 | 1 |
| Emerging Market for Clinical Trials China - Regulatory Landscape | 66 | 15 |
| Introduction | 66 | 1 |
| Drug Administration Law | 66 | 1 |
| Implementing Regulation of Drug Administrative Law | 67 | 1 |
| Good Clinical Practices (GCP) of Pharmaceutical Products (1999) | 67 | 1 |
| Work Rules for Clinical Research of Drugs (2000) | 68 | 1 |
| Structure and Procedure for Monitoring Adverse Drug Reactions in China | 69 | 1 |
| The Ministry of Health | 70 | 1 |
| State Food and Drug Administration (SFDA) | 70 | 1 |
| Clinical Trials Registry China (ChiCTR) | 71 | 1 |
| Clinical Trial Regulation in China | 72 | 1 |
| Approval Process for Clinical Trials in China | 72 | 1 |
| Number of Days Required For Getting the Approval for Clinical Trials (Individual Procedures) | 73 | 1 |
| Approval Process for Clinical Trials in China for Imported Drugs | 74 | 1 |
| Number of Days Required For Getting the Approval for Clinical Trials for Imported Drugs (Individual Procedures) | 75 | 1 |
| Documents Required With the Investigator of Clinical Trials | 75 | 1 |
| Documents to Be Located In the Files of Investigator before the Commencement of Clinical Trials | 75 | 1 |
| Documents to Be Located In the Files of Investigator during the Clinical Conduct of Trials | 76 | 1 |
| Documents to Be Located In the Files of Investigator after Completion of Clinical Trials | 76 | 1 |
| Documents Required With the Sponsor of Clinical Trials | 77 | 1 |
| Documents to Be Located In the Files of Sponsor before the Commencement of Clinical Trials | 77 | 1 |
| Documents to Be Located In the Files of Sponsor during the Clinical Conduct of Trials | 78 | 1 |
| Documents to Be Located In the Files of Sponsor after Completion of Clinical Trials | 78 | 1 |
| Recent Regulatory Changes in Clinical Trials | 79 | 1 |
| Longer lead-times on specified exports | 79 | 1 |
| Need for Chinese-based applicant. | 79 | 1 |
| Government Incentives | 79 | 1 |
| Activity of International Pharmaceutical Companies in China | 80 | 1 |
| Emerging Market for Clinical Trials China - CRO Landscape | 81 | 12 |
| Classification of CROs in China | 81 | 1 |
| Number of CROs in China Based on Types of Services Rendered | 82 | 1 |
| Acquisitions of Chinese CROs | 83 | 1 |
| Recent Alliances of Chinese CROs | 83 | 1 |
| CRO Profiles | 84 | 1 |
| BO JI Medicine Services Co. Ltd | 84 | 1 |
| Business Description | 84 | 1 |
| Giant Med-Pharma Services Inc | 85 | 1 |
| Business Description | 85 | 1 |
| InCROM | 86 | 1 |
| Business Description | 86 | 1 |
| Pharmaron | 87 | 1 |
| Business Description | 87 | 1 |
| Venturepharm Service Group (VPS) | 88 | 1 |
| Business Description | 88 | 1 |
| PPD | 89 | 1 |
| Business Description | 89 | 1 |
| CCBR-SYNARC | 90 | 1 |
| Business Description | 90 | 1 |
| Quintiles | 91 | 1 |
| Business Description | 91 | 1 |
| Kendle | 92 | 1 |
| Business Description | 92 | 1 |
| Emerging Market for Clinical Trials China - Appendix | 93 | 5 |
| Market Definitions | 93 | 1 |
| Abbreviations | 93 | 1 |
| Research Methodology | 94 | 2 |
| Coverage | 94 | 1 |
| Secondary Research | 95 | 1 |
| Primary Research | 95 | 1 |
| Expert Panel Validation | 95 | 1 |
| Contact Us | 96 | 1 |
| Disclaimer | 96 | 1 |
| Sources | 96 | 2 |